Phase III data continues to show efficacy of Tanzeum/Eperzan in T2D - GSK

New data from secondary analyses of four randomised Phase III studies show that Type 2 Diabetes patients enrolled in the studies who remained on once-weekly Tanzeum/Eperzan (albiglutide), from Glaxo Smith Kline, continued to show blood glucose lowering at three years, consistent with results at the one year (52 week) primary endpoint. In the four studies, entitled Harmony 1, 2, 4 and 5, the primary endpoint of blood glucose lowering, defined as the reduction of HbA1c (glycated haemoglobin, a measure of blood glucose levels) from baseline was assessed at 52 weeks (results previously announced). Those patients who remained in the study until year three continued to receive randomised treatment, as pre-specified in the study protocol, to further assess the efficacy and safety profile of albiglutide.

Safety data for albiglutide in these studies were also consistent with the results observed up to year one. Commonly reported adverse reactions included nausea, diarrhoea, and injection site reactions. Tanzeum/Eperzan was approved in the US and EU early in 2014. Data were presented at the 74th Scientific Sessions of the American Diabetes Association.